

What is claimed is:

1. A method of inhibiting a transforming growth factor  $\beta 2$  (TGF $\beta 2$ ) comprising contacting said TGF $\beta 2$  with a nucleic acid ligand of TGF $\beta 2$ .


2. The method of claim 1, wherein the nucleic acid ligand of TGF $\beta 2$  is a ligand comprising a ligand having a nucleotide sequence selected from the group consisting of SEQ ID NOS:21-87, 89, 91-93, 109, 111, 114-116, 118-121, 129, 131, 138, 140, 144, 146-181, 184-189, 192, and 193.

3. The method of claim 1 wherein said nucleic acid ligand is conjugated to polyethylene glycol (PEG).

4. The method of claim 3 wherein said PEG has a molecular weight of about between 10-80 K.

5. The method of claim 3 wherein said PEG has a molecular weight of about 20-45 K.

6. The method of claim 1 wherein said ligand is



wherein

X=PEG, and

LIGAND=  
rGrGrArGrGfUfUrAfUfUrAfCrArGrArGfUfCfUrGfUfUrArGfCfUrGfUrAfCfUfCfC-3'-3'-dT  
(SEQ ID NO:115), wherein rG is 2'OH G, rA is 2'OH A, fU is 2'F U and fC is 2'F C.

7. A method for targeting a nucleic acid ligand to a site in a patient comprising TGF $\beta 2$  comprising:

covalently linking said nucleic acid ligand to a Non-Immunogenic, High Molecular

Weight Compound or Lipophilic Compound to form a Complex, and administering said

Complex to said patient, whereby said nucleic acid ligand is targeted to a site in a patient comprising TGFβ2.


8. The method of claim 7, wherein the nucleic acid ligand of TGFβ2 is a ligand comprising a ligand having a nucleotide sequence selected from the group consisting of SEQ ID NOS:21-87, 89, 91-93, 109, 111, 114-116, 118-121, 129, 131, 138, 140, 144, 146-181, 184-189, 192, and 193.

9. The method of claim 7 wherein said nucleic acid ligand is conjugated to polyethylene glycol (PEG).

10. The method of claim 9 wherein said PEG has a molecular weight of about between 10-80 K.

11. The method of claim 9 wherein said PEG has a molecular weight of about 20-45 K.

12. The method of claim 7 wherein said ligand is



wherein

X=PEG, and

LIGAND=  
rGrGrArGrGfUfUrAfUfUrAfCrArGrArGfUfCfUrGfUfUrArGfCfUrGfUrAfCfUfCfC-3'-3'-dT  
(SEQ ID NO:115), wherein rG is 2'OH G, rA is 2'OH A, fU is 2'F U and fC is 2'F C.

13. A method for treating a TGFβ2-mediated pathological conditions comprising administering a nucleic acid ligand capable of binding to TGFβ2 to a patient in need thereof.


14. The method of claim 13, wherein the nucleic acid ligand of TGFβ2 is a ligand comprising a ligand having a nucleotide sequence selected from the group consisting of SEQ ID NOS:21-87, 89, 91-93, 109, 111, 114-116, 118-121, 129, 131, 138, 140, 144, 146-181, 184-189, 192, and 193.

15. The method of claim 13 wherein said nucleic acid ligand is conjugated to polyethylene glycol (PEG).

16. The method of claim 15 wherein said PEG has a molecular weight of about between 10-80 K.

5 17. The method of claim 15 wherein said PEG has a molecular weight of about 20-45 K.

18. The method of claim 13 wherein said ligand is



wherein

X=PEG, and

LIGAND=

rGrGrArGrGfUfUrAfUfUrAfCrArGrArGfUfCfUrGfUfUrArGfCfUrGfUrAfCfUfCfC-3'-3'-dT

(SEQ ID NO:115), wherein rG is 2'OH G, rA is 2'OH A, fU is 2'F U and fC is 2'F C.